osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['lcsm,(-blcsm)', 'osimertinib', 'lazertinib', 'sclc', 'nsclc', 'chrysalis-2']
chrysalis-2: amivamtamab+lazertinib post-osimertinib and platinum-based chemotherapy in pts (n=162) with egfr-mutant advanced nsclc--&gt; orr 33% md dor 9.6 mo md pfs 5.1 mo md os 14.8 mo. #lcsm #asco22 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own